APA (7th ed.) Citation

EM, O., CR, C., JP, L., ZA, W., GA, F., RA, W., . . . RH, V. (2026). Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated metastatic pancreatic adenocarcinoma. Journal for immunotherapy of cancer, 14(1), . https://doi.org/10.1136/jitc-2025-012864

Chicago Style (17th ed.) Citation

EM, O'Reilly, et al. "Clinical and Translational Results from a Phase 1 Trial of Gemcitabine/nab-paclitaxel with Nivolumab/ipilimumab or Hydroxychloroquine/ipilimumab in Untreated Metastatic Pancreatic Adenocarcinoma." Journal for Immunotherapy of Cancer 14, no. 1 (2026). https://doi.org/10.1136/jitc-2025-012864.

MLA (9th ed.) Citation

EM, O'Reilly, et al. "Clinical and Translational Results from a Phase 1 Trial of Gemcitabine/nab-paclitaxel with Nivolumab/ipilimumab or Hydroxychloroquine/ipilimumab in Untreated Metastatic Pancreatic Adenocarcinoma." Journal for Immunotherapy of Cancer, vol. 14, no. 1, 2026, https://doi.org/10.1136/jitc-2025-012864.